Arecor Therapeutics Rapid Insulin Trial Results Positive

Today (September 20), Arecor Therapeutics announced positive results from a Phase 1 clinical trial of its rapid-acting insulin concentrate.

The company’s candidate, called AT278, is formulated using it Arestat technology and is designed to significantly accelerate the absorption of insulin after injection. This is done for more effective and convenient management of blood glucose levels in people with high daily insulin requirements.

High insulin requirements

Thomas Pieber, Investigator Study ARE-278-102said: “The fast-acting characteristics of AT278, even at a fivefold increase in concentration, are clinically significant, suggesting that AT278 may significantly improve postprandial glucose control and reduce the number of daily injections for people with diabetes. who have a great need for insulin.’

In a double-blind, randomized, single-dose, two-period phase 1 clinical trial research The pharmacokinetic (PK) and pharmacodynamic (PD) profile of AT278 was compared with NovoRapid, the current gold standard of care, in 38 patients with type 1 diabetes.

Glucose clamp

The test was carried out under glucose clamp conditions Medical University of Graz and Joanneum Research in Austria, an internationally recognized center of excellence in diabetes research.

The PK/PD profile of AT278 was accelerated compared to NovoRapid. After dosing, AT278 showed a faster onset of insulin action compared to NovoRapid, as demonstrated by an earlier onset of action.

Fewer injections

Sarah Howell, chief executive officer of Arecor, said: “By reducing injection volumes and fewer injections per day, while providing the potential to improve blood glucose control through a better PK/PD profile, AT278 has the potential to become the gold standard of insulin. treatment for the growing population of people living with diabetes who have high daily insulin requirements, especially those with type 2 diabetes.

A truly rapid-acting insulin concentrate such as AT278 is also critical to the development of next-generation miniaturized insulin delivery devices, where the size of such devices is often a barrier to patient use.” Arecor Therapeutics Rapid Insulin Trial Results Positive

Back to top button